Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000241042 | SCV000300663 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-09-08 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Counsyl | RCV000241042 | SCV000785632 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2017-10-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001385724 | SCV001585686 | pathogenic | Hereditary breast ovarian cancer syndrome | 2020-01-02 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant has been reported in individuals in the Leiden Open-source Variation Database (PMID: 21520333). ClinVar contains an entry for this variant (Variation ID: 254524). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Ile1258Metfs*6) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. |
Ambry Genetics | RCV002347946 | SCV002620761 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-03-11 | criteria provided, single submitter | clinical testing | The c.3774_3775delAA pathogenic mutation, located in coding exon 10 of the BRCA2 gene, results from a deletion of two nucleotides at nucleotide positions 3774 to 3775, causing a translational frameshift with a predicted alternate stop codon (p.I1258Mfs*6). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |